NCT03170895View on ClinicalTrials.gov

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

February 1, 2020

Study Completion Date

March 1, 2020

Conditions
AMLFLT3-ITD Mutation
Interventions
DRUG

Sorafenib

Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma

DRUG

Omacetaxine Mepesuccinate Injection

Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03170895 - Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | Biotech Hunter | Biotech Hunter